Progressive growth and metastasis of solid tumors require angiogenesis, or the formation of new blood vessels. Endostatin is a 20 -kDa carboxy -terminal fragment of collagen XVIII that has been shown to inhibit endothelial cell proliferation and tumor angiogenesis. Replication -deficient recombinant adenovirus ( rAd ) vectors were constructed, which encoded secreted forms of human and mouse endostatin ( HECB and MECB, respectively ), and, as a control, human alkaline phosphatase ( APCB ). Accumulation of endostatin was demonstrated in supernatants of cultured cells infected with the endostatin rAds. These supernatants disrupted tubule formation, inhibited migration and proliferation, and induced apoptosis in human dermal vascular endothelial cells or human vascular endothelial cells. Endostatin -containing supernatants had no effect on the proliferation of MidT2 -1 mouse mammary tumor cells in vitro. A pharmacokinetic study of MECB in immunocompetent FVB mice demonstrated a 10 -fold increase of serum endostatin concentrations 3 days after intravenous administration of 1Â10 10 particles of this rAd ( 215 -257 ng / mL compared to 12 -38 ng / mL in control rAd -treated mice ). Intravenous administration of MECB reduced b -FGF stimulated angiogenesis into Matrigel plugs by 38%. Intratumoral MECB inhibited growth of MidT2 -1 syngeneic mammary tumors in FVB mice, but had minimal impact on the growth of MDA -MB -231 human breast tumors in SCID mice. Intravenous therapy with MECB also initially inhibited growth of MidT2 -1 tumors, but this activity was subsequently blocked by induced anti -rAd antibodies. In summary, endostatin gene therapy effectively suppressed angiogenic processes in vitro and in vivo in several model systems. Cancer Gene Therapy ( 2001 ) 8, 982 -989
2,y y y y y y y y y y y y y y y y A ngiogenesis is a complex process, which includes the activation, proliferation, and migration of endothelial cells; disruption of vascular basement membranes; formation of vascular tubes and networks; and their linkage to pre -existing vascular networks. 1, 2 It is involved in a number of normal and pathological biological processes, such as wound healing, several ocular disorders, and neoplasia. 2 Specific inhibitors of angiogenesis may have therapeutic roles in these diseases. In the last few years, a number of protein or peptide molecules have been identified with antiangiogenic activity in vitro and in vivo. Some of them are subfragments of other larger proteins, such as plasminogen or collagen XVIII in the cases of angiostatin and endostatin, respectively. Endostatin was first isolated from conditioned media (CM ) of cultured EOMA ( hemangioendothelioma ) cells and was found to be identical to a 20 -kDa C -terminal fragment of collagen XVIII. 3 Endostatin is a specific inhibitor of endothelial cell proliferation in vitro, and systemic therapy with endostatin protein has been shown to suppress tumor-induced angiogenesis and tumor growth. 3, 4 Notably, these studies required daily parenteral injections of large amounts of recombinant protein, illustrating a common difficulty in the pharmacologic use of therapeutic proteins.
Gene therapy approaches may have advantageous properties as methods for delivery of systemic protein drugs, especially wherein long -term production and secretion from a conveniently transduced tissue can be effected. The goal of this study was to demonstrate, as a proof of principle, transgene -derived secreted local or systemic antiangiogenic protein therapy. A recombinant adenovirus ( rAd ) vector was selected because of its transduction efficiency and versatility by several dosage routes (e.g., intratumoral and intravenous ), despite its anticipated immune -mediated restrictions on redosing. Endostatin was chosen as the encoded protein based on its well -characterized activity as an antiangiogenic protein. Our results demonstrate both the potential therapeutic efficacy as well as the problems of this approach.
MATERIALS AND METHODS

Cell lines
The 293 cell line was obtained from Microbix and cultured in Dulbecco's modified Eagle's medium ( DMEM; Gibco, Grand Island, NY ) with 10% fetal bovine serum (FBS; Gibco ). Human primary endothelial cells, HUVEC ( human umbilical vein endothelial cells) and HDEC (human dermal endothelial cells ), were purchased from Clonetics (San Diego, CA ) and cultured in manufacturer's growth medium. ARPE -19 is an immortalized cell line derived from human retinal pigment epithelial cell and was purchased from ATCC (Rockville, MD ). The MidT2 -1 clonal cell line was derived from female MMTV Polyomavirus Middle T ( PyV MidT ) transgenic mouse mammary tumors as previously described 5 and are syngeneic for the immunocompetent FVB mouse strain. MDA -MB -231 human breast adenocarcinoma cells were purchased from ATCC and cultured in DMEM with 10% FBS. All cell lines were cultured at 378C and 5% CO 2 .
Construction and purification of rAd carrying endostatin cDNA cDNA containing the coding sequences of human and mouse endostatin were obtained from the IMAGE Consortium. A secretion signal peptide sequence from preprotrypsin (ACC ATG TCT GCA CTT CTG ATC CTA GCT CTT GTT GGA GCT GCA GTT GCT ) was added to the 5 0 end of each cDNA by polymerase chain reaction. They were then subcloned into an adenoviral shuttle vector 6 containing a cytomegalovirus (CMV ) promoter for transgene expression. Shuttle plasmids were cotransformed into Escherichia coli ( BJ5183 ) with a plasmid carrying type 5 adenoviral genomic DNA with E3 region deletion. DNA from recombinant colonies was purified and verified by restriction enzyme digestion and transgene sequencing. DNA was linearized with PacI and used to transfect 293 cells for generation of rAd carrying the human or mouse endostatin (HECB or MECB, respectively ). A control vector, APCB, constructed by the same procedure carried the secreted form of human alkaline phosphatase in place of endostatin. Viral vectors were propagated and purified as previously described. 7 Viral particle number ( PN ) was determined using anion exchange high -performance liquid chromatography 8 and A 260 nm measurement in 0.1% SDS (wt /vol ). 9 Viral construct infectivity was confirmed using a flow cytometry-based adenovirus infection assay and expressed as cellular infectious units (ciu ). 10 Production of CM ARPE-19 cells were seeded in 10-cm plates and infected with HECB, MECB, or APCB, respectively, at dosage of 1Â10 9 PN /mL for 2 hours. Viruses were washed off with phosphate -buffered saline (PBS ). Cells were then incubated in serum -free medium containing 0.1% bovine serum Figure 2 . Inhibition of endothelial cell proliferation in vitro. HDEC or MidT2 -1 mouse mammary tumor cells were seeded into six -well plates at a density of 5Â10 4 cells / well, allowed to attach for 8 hours, and starved with serum -free medium overnight. Cells were then treated with CM for 8 hours, followed by complete medium for an additional 5 days before cell quantitation. 
Endostatin expression from HECB and MECB
To detect endostatin expression, CM was analyzed by Western blot using a polyclonal antibody generated against a conjugated peptide (N -CWPQKSVWHGSDPNGRRL -C ) ( Multiple Peptide Systems, San Diego, CA ). Endostatin concentration in CM was measured by the Accucyte human or murine endostatin enzyme -linked immunosorbent assay ( ELISA ) kit (Cytimmune Sciences, College Park, MD ) according to the manufacturer's instructions.
In vitro endothelial cell proliferation assays
Human dermal endothelial cells or MidT2 -1 cells were seeded in six -well plates at 5Â10 4 cells / well for 8 hours and then starved with serum -free medium overnight. Cells were then treated with CM at 1 mL /well for 8 hours before complete medium was added to each well at 1 mL / well. Cells were incubated in 378C with 10% CO 2 for 5 days before they were counted with a hemacytometer.
In vitro endothelial cell migration assays
HUVEC were grown to 80 -90% confluency in a BIOCOAT Collagen I T-75 flask (Becton Dickinson Biosciences, Franklin Lakes, NJ ) and then labeled in situ with 5 mM Calcein -AM in DMEM containing 2% FBS for 2 hours at 378C. After washing, cell monolayers were briefly trypsinized, and cell pellets were resuspended in DMEM supplemented with 0.1% BSA. Cells were placed in 3 -mm FALCON HTS FluoroBlok Cell Culture Inserts (Becton Dickinson Biosciences ) at a density of 1Â10 6 cells/insert. CM from different vector-infected cells (see above ) were added into the inserts and incubated with cells for 30 minutes before DMEM containing 1% FBS and basic FGF (b -FGF, 20 ng/ mL; R&D Systems, Minneapolis, MN ) was added to the lower wells as a chemoattractant. Cells were allowed to migrate for 3 hours. Fluorescence of cells that had migrated through the FALCON HTS FluoroBlok Inserts was measured on a Cytofluor 4000 plate reader ( PerSeptive Biosystems, Framingham, MA ) using excitation/ emission wavelengths of 485/530 nm.
In vitro endothelial cell differentiation assays
Endothelial cell differentiation assays were performed as described. 11 Human dermal endothelial cells were seeded in extracellular matrix ( ECM )-coated 24-well plates ( Biocoat Cellware; Becton Dickinson Biosciences ) at 40,000 cells/well. CM was added into the wells at 200 mL /well. Cell growth and differentiation was documented 24 hours later.
In vitro endothelial cell apoptosis assays HUVEC were infected in six -well plates with different vectors at 1Â10 9 PN /mL for 4 hours. Viruses were then washed off with PBS and cells were incubated with complete medium for 48 hours. Cells were trypsinized, stained with annexin V-FITC (Roche Molecular Biochemicals, Indianapolis, IN ), and analyzed by FACS.
Animal care
Mice were obtained from SPRI breeding colonies. All mice were maintained in a VAF barrier facility. Animal procedures were performed in accordance with the rules set forth in the NIH Guide for the Care and Use of Laboratory Animals and approved by the SPRI Animal Care and Use Committee.
Pharmacokinetic study
Each female FVB mouse was injected with 1Â10 10 PN MECB or APCB via the tail vein on day 0. Mice were APCB HECB MECB MEDIUM Figure 4 . Inhibition of endothelial cell differentiation in vitro. HDEC were seeded into 24 -well plates coated with ECM at a density of 40,000 cells / well. CM was added into the wells at 200 mL / well. Cell growth and differentiation were documented as observed 24 hours later. sacrificed and serum collected on days 3, 4, 5, 6, and 7. In addition, serum was collected from three untreated mice to establish baseline levels of endogenous endostatin ( day 0 value ). Samples were assayed using the Accucyte murine endostatin ELISA kit ( see above ) according to the manufacturer's instructions. Endostatin levels for any two treatment groups on each day were compared using Students' t test ( Statview Software; SAS Institute, Cary, NC ).
Matrigel assay
Growth factor -reduced Matrigel matrix without phenol red was purchased from Becton Dickinson Biosciences. Human b -FGF was from R&D Systems. b -FGF was dissolved in sterile PBS buffer containing 0.1 -1% BSA and 1 mM DTT to make 25 mg /mL stock solution. Matrigel was liquidized slowly at 48C. Each female FVB mouse was injected with 0.5 mL of unpolymerized Matrigel containing b-FGF at a concentration of 700 ng /mL subcutaneously along the abdominal midline. Mice were given one intravenous injection of 1Â10 10 PN MECB or APCB via the tail vein 3 days before Matrigel injection. Matrigel plugs were harvested 7 days later and put into Drabkin's solution for hemoglobin ( Hgb ) assay (Sigma, St. Louis, MO ). Briefly, Matrigel plugs removed from surrounding tissues were resuspend in 2 mL of Drabkin's solution, mixed well, and rocked for 2 days at 48C. Absorption of the supernatants containing total Hgb was measured at 540 nm and the Hgb levels calculated using a Hgb standard curve run in parallel with the unknowns.
Intratumoral administration
MidT2 -1 model. Each female FVB mouse was injected with 5Â10 6 MidT2 -1 syngeneic mouse mammary tumor cells into the mammary fat pad.
MDA -MB -231 model. Each female SCID mouse was injected with 5Â10
6 MDA -MB -231 human breast tumor cells into the mammary fat pad. Treatment was started 16 days later when large tumors had formed. Adenovirus (1Â10 10 PN ) or vehicle was administered intratumorally on days 0 and 5 in a volume of 0.1 mL. Tumor measurements were recorded during the course of the study and serum samples were collected on day 8 for determination of circulating endostatin levels as described above. Tumor volumes were calculated as lengthÂwidthÂdepth. Tumor volumes for any two treatment groups on each day were compared using Students' t test ( Statview Software; SAS Institute ).
Intravenous administration
Each female FVB mouse was injected with 1Â10 
(2)
Serum Endostatin (ng/ml) Figure 6 . Pharmacokinetic study in immune -competent FVB mice. Mice were given one intravenous dose of 1Â10 10 PN MECB on day 0. Mean ± SEM. n = 3 mice per group.
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JIN, BOOKSTEIN, WILLS, ET AL: ENDOSTATIN ANTIANGIOGENESIS tumors had formed. Adenovirus (1Â10 10 PN / dose ) or vehicle was administered via the tail vein on days 0, 7, and 14 in a volume of 0.1 mL. Tumor sizes were analyzed as above, and serum samples were collected on day 18 for antiAd antibody testing.
Neutralizing antibody assay
Modification of a previously described assay 12 was used to determine the level of neutralizing antibodies in serum. Serial dilution ( 1:2 ) of the serum sample of interest ( starting at 1:20, 1:40, 1:80, etc. ) was pipetted in a 96-well format. A replication-deficient (deleted for E1, E3, pIX ) type 5 human rAd vector 13 expressing the Green Fluorescent Protein under control of the CMV immediate early promoter ( GFCB ) was used. The appropriately diluted serum sample was allowed to incubate with GFCB at a final concentration of 4Â10 8 particles /mL for 1 hour at 378C. The serum /virus mixture was transferred onto HeLa cells plated at 1Â10 4 cells/well in a 96 -well format. The virus was allowed to infect the cells overnight. The relative fluorescence was measured the following day on a CytoFluor 4000 Fluorescence Multiwell Plate Reader ( PerSeptive Biosystems, Foster City, CA ) to assay neutralizing capacity.
RESULTS
Endostatin protein expression from rAds
rAds encoding human and mouse endostatin (HECB and MECB, respectively ) were constructed, produced, and purified as described in Materials and Methods. Endostatin gene expression from HECB or MECB was examined by Western blot analysis ( Fig 1A ) and ELISA ( Fig 1B ) . Human or mouse endostatin was detected in both CM and cell lysates from rAd -infected ARPE -19 cells 24 hours postinfection. The concentrations of human or mouse endostatin in the CM, measured by ELISA, were 2.1 g/mL for HECB and 1.8 g/ mL for MECB. No endostatin was detected from the CM or cell lysate of control APCB -infected cells.
Biological activity of HECB -and MECB -derived endostatin
We sought to verify the biological activity of rAd -expressed endostatin in several in vitro assays representing various important aspects of the angiogenic process, including endothelial cell proliferation, migration, and differentiation in response to ECM, which plays a dynamic role in endothelial cell biology. To determine whether secreted endostatin from HECB or MECB can inhibit endothelial cell proliferation, human dermal vascular endothelial cells were treated with CM containing human or mouse endostatin followed by stimulation with complete medium. As shown in Figure 2 , CM with endostatin inhibited HDEC proliferation by approximately 50% compared to CM without endostatin, whereas the growth of MidT-2-1 tumor cells was not affected. Similarly, CM containing human or mouse endostatin inhibited HUVEC migration through porous membranes by approximately 40% for human endostatin and 50% for mouse endostatin compared to control CM (Fig 3 ) . ECM -coated plates were used to examine the effect of secreted endostatin on in vitro tubule formation, which assesses migration and differentiation of human dermal endothelial cells. As shown in Figure 4 , tube -like structures formed by endothelial cells were abrogated by CM containing the secreted human or mouse endostatin. By contrast, CM from APCB -infected cells had no observable effect on tube structure.
HECB -and MECB -induced endothelial cell apoptosis
Although the mechanism of endostatin's antiangiogenic activity is unknown, it has been shown that endostatin specifically induces endothelial cell apoptosis. 14 We tested the effects of HECB and MECB on the induction of endothelial cell apoptosis. HUVEC infected with HECB or MECB demonstrated markedly enhanced apoptosis 24 hours postinfection compared with the control vector ( Fig 5 ) . CM containing human or mouse endostatin were also used to induce endothelial cell apoptosis, but the effect was not as dramatic as direct infection with Ad vector (data not shown).
Serum endostatin levels after intravenous MECB injection
As a prelude to the use of rAd endostatin vectors in vivo, a pharmacokinetic study of intravenously injected MECB was performed in immune -competent FVB mice. Although the particular disposition of these rAds was not followed, more than 90% of one rAd dose administered by this route has been shown to be retained in the liver. After intravenous injection of 1Â10 10 PN MECB, serum endostatin concentrations rose to 215 -257 ng/ mL during days 3 -6 (Fig 6 ) , which was a $10 -fold increase over pretreatment or APCB -treated levels (range 12 -38 ng/ mL ). By day 7, serum endostatin levels had fallen to 131 ± 30 ng /mL ( ± SEM ).
Matrigel angiogenesis assay
Angiogenic factors, such as b -FGF, induce the growth of new blood vessels into solid plugs of Matrigel injected subcutaneously into mice. Quantitation of blood Hgb content in these plugs serves as a surrogate marker for angiogenesis. As shown in Figure 7 , the Hgb content of Matrigel plugs containing b -FGF was 10 -fold higher than the Hgb content of Matrigel plugs containing no additional angiogenic factors, indicating successful measurement of proangiogenic activity of b -FGF in this assay. In mice with Matrigel plugs containing b -FGF, MECB therapy suppressed angiogenesis by 38% compared to mice treated with APCB (P= .018 ). Circulating endostatin levels were determined 10 days after intravenous dosing to confirm and extend the earlier PK study. Mice treated with MECB had serum endostatin level of 136 ng /mL (groups 2 and 4 ) compared to those dosed with APCB with 36 ng/ mL ( group 1 ) and 40 ng /mL (group 3), respectively.
Antitumor activity of MECB
The antitumor activity of MECB was tested in the syngeneic MidT2 -1 mammary tumor model in FVB mice and in the MDA -MB -231 human breast tumor model in SCID mice. Two intratumoral doses of 1Â10 10 PN MECB suppressed growth of MidT2 -1 mammary fat pad tumors ( P .01; Fig 8A ) , but had minimal impact on the growth of MDA -MB -231 tumors (Fig 8B ) . The first intravenous dose of MECB also retarded the growth of MidT2 -1 tumors, but subsequent doses were minimally effective ( Fig  8C ) presumably because mice developed neutralizing antibodies against rAd. Anti -rAd antibodies were undetectable in mice dosed with vehicle (n =10 ); however, in mice dosed with APCB or MECB, 4 mice had titers of 1:1280, 5 mice had titers of 1:2560, and 10 mice had titers greater than 1:2560. 
DISCUSSION
Both positive and negative regulators of the process of angiogenesis have been described. Tumor cells are known to secrete many proangiogenic factors, such as fibroblast growth factor and vascular endothelial growth factor, consistent with the requirement of angiogenesis for progressive tumor growth.
15 Surprisingly, tumors may also produce angiogenesis inhibitors. Endostatin, a 20 -kDa Cterminal fragment of collagen XVIII and a specific inhibitor of endothelial cell proliferation, migration, and angiogenesis 3,16 -18 was initially identified in supernatants of cultured tumor cells. The role of this peptide in natural human tumorigenesis is not yet known. 14, 19, 20 Inhibition of angiogenesis by endostatin or other proteins is thought to be a promising new strategy in cancer therapy. 15 However, its widespread application has been hampered by difficulties in the large -scale production of the antiangiogenic proteins. This limitation may be resolved by in vivo delivery and expression of the antiangiogenic genes. 21 -26 In this study, rAds expressing secreted forms of human (HECB ) and mouse (MECB ) endostatin were shown to be efficient agents for endostatin gene therapy. Immortalized human retinal pigment epithelial (ARPE -19) cells secreted high levels of endostatin into the surrounding medium after rAd transduction. This CM inhibited the proliferation of human dermal endothelial cells, but had no effect on the proliferation of ARPE -19 epithelial cells ( data not shown ) and MidT2 -1 mouse mammary carcinoma cells. Transduction of human dermal endothelial cells with HECB or MECB also suppressed the normal response of cellular differentiation into tubules in vitro. In addition, endostatin inhibited proliferation, suppressed migration, and induced apoptosis of HUVEC. Intravenous gene therapy in immune-competent FVB mice produced a 10 -fold increase of circulating endostatin levels within 3 days after intravenous administration of 1Â10 10 PN MECB. These elevated levels of circulating endostatin were maintained until day 6 and began to fall by day 7. The same single, intravenous dose of MECB suppressed b-SSFGF -stimulated angiogenesis into Matrigel plugs by 38%.
The antitumor activity of MECB was tested in two in vivo tumor models -the syngeneic MidT2 -1 mammary tumor model in FVB mice and the MDA -MB -231 human breast tumor model in immunodeficient SCID mice. Two intratumoral doses of MECB halted further growth of MidT2 -1 mammary fat pad tumors, but had minimal impact on the growth of MDA -MB-231 tumors. The first intravenous dose of MECB had a similar cytostatic effect on MidT2 -1 tumors. However, further dosing had little impact on tumor growth rates that corresponded to the development of neutralizing antibodies against rAd. Because endostatin had no effect on MidT2 -1 cell proliferation in vitro, we conclude that endostatin gene therapy halted MidT2 -1 tumor growth in FVB mice by suppressing tumor angiogenesis in vivo. Further investigation is required into the reason why endostatin had little effect on MDA -MB -231 tumor growth in SCID mice. SCID blood vessel endothelial cells may be less sensitive to endostatin than FVB endothelial cells, or the growth of MidT2 -1 tumors might be more dependent on continuing angiogenesis to support tumor growth than MDA -MB -231 tumors. Feldman et al 25 used a mouse tumor cell line, which was relatively resistant to adenovirus infection, to demonstrate a 40% reduction in tumor size in nude mice after in vivo endostatin gene therapy. This study confirmed the sensitivity of blood vessel endothelial cells in nude mice to endostatin-mediated suppression of angiogenesis.
In conclusion, gene therapy has now been employed for the delivery of angiogenesis inhibitors to suppress tumor growth and metastasis. It represents a more cost -effective and convenient way of delivering steady-state levels of antiangiogenic factors to the tumor. Our study provides further evidence that antiangiogenic gene therapy can be used as an effective approach in cancer treatment, and translation of antiangiogenic gene therapy from laboratory to clinic may soon become a reality.
